Abstract:Our previous work revealed that Nrf1αexerts a tumor-repressing effect because its genomic loss (to yieldNrf1α-/-) results in oncogenic activation of Nrf2 and target genes. Interestingly,β-catenin is concurrently activated by loss of Nrf1αin a way similar toβ-catenin-driven liver tumor. However, a presumable relationship between Nrf1 andβ-catenin is not yet established. Here, we demonstrate that Nrf1 enhanced ubiquitination ofβ-catenin for targeting proteasomal degradation. Conversely, knockdown of Nrf1 by its short hairpin RNA (shNrf1) caused accumulation ofβ-catenin so as to translocate the nucleus, allowing activation of a subset of Wnt/β-catenin signaling responsive genes, which leads to the epithelial-mesenchymal transition (EMT) and related cellular processes. Such silencing of Nrf1 resulted in malgrowth of human hepatocellular carcinoma, along with malignant invasion and metastasis to the lung and liver in xenograft model mice. Further transcriptomic sequencing unraveled significant differences in the expression of both Wnt/β-catenin-dependent and Wnt/β-catenin-independent responsive genes implicated in the cell process, shape, and behavior of the shNrf1-expressing tumor. Notably, we identified thatβ-catenin is not a target gene of Nrf1, but this CNC-bZIP factor contributes to differential or opposing expression of other critical genes, such asCDH1,Wnt5A,Wnt11A,FZD10,LEF1,TCF4,SMAD4,MMP9,PTEN,PI3K,JUN, andp53, each of which depends on the positioning of distinctcis-regulatory sequences (e.g., ARE and/or AP-1 binding sites) in the gene promoter contexts. In addition, altered expression profiles of some Wnt/β-catenin signaling proteins were context dependent, as accompanied by decreased abundances of Nrf1 in the clinic human hepatomas with distinct differentiation. Together, these results corroborate the rationale that Nrf1 acts as abona fidedominant tumor repressor, by its intrinsic inhibition of Wnt/β-catenin signaling and relevant independent networks in cancer development and malignant progression.

The Tumor Suppressor Protein Menin Inhibits NF-κB-mediated Transactivation Through Recruitment of Sirt1 in Hepatocellular Carcinoma

SIRT1 Facilitates Hepatocellular Carcinoma Metastasis by Promoting PGC-1α-mediated Mitochondrial Biogenesis.

STAT1 Inhibits Human Hepatocellular Carcinoma Cell Growth Through Induction of P53 and Fbxw7

Menin Promotes Hepatocellular Carcinogenesis And Epigenetically Up-Regulates Yap1 Transcription

Functional Interaction Between Tumor Suppressor Menin And Activator Of S-Phase Kinase

Tumor Necrosis Factor Α-Induced Protein 1 As a Novel Tumor Suppressor Through Selective Downregulation of CSNK2B Blocks Nuclear Factor-Κb Activation in Hepatocellular Carcinoma.

SIRT1 Inhibits Hepatocellular Carcinoma Metastasis by Promoting M1 Macrophage Polarization Via NF-κB Pathway

Inhibition of SIRT1 Relieves Hepatocarcinogenesis Via Alleviating Autophagy and Inflammation

Nrf1 is Endowed with a Dominant Tumor-Repressing Effect Onto the Wnt/β-Catenin-Dependent and Wnt/β-Catenin-Independent Signaling Networks in the Human Liver Cancer

NFATc1 is a Tumor Suppressor in Hepatocellular Carcinoma and Induces Tumor Cell Apoptosis by Activating the FasL‐mediated Extrinsic Signaling Pathway

Menin Enhances C-Myc-mediated Transcription to Promote Cancer Progression

Suppression of Lung Adenocarcinoma Through Menin and Polycomb Gene-Mediated Repression of Growth Factor Pleiotrophin

Menin regulates lipid deposition in mouse hepatocytes via interacting with transcription factor FoxO1

Oncogenic activation of Nrf2 by specific knockout of Nrf1α that acts as a dominant tumor repressor

MEN1 deficiency stabilizes PD‐L1 and promotes tumor immune evasion of lung cancer

Hepatic Menin Recruits SIRT1 to Control Liver Steatosis Through Histone Deacetylation.

The TNF-α/ROS/HIF-1-induced upregulation of FoxMI expression promotes HCC proliferation and resistance to apoptosis.

Interplay between Menin and K-Ras in Regulating Lung Adenocarcinoma

Menin in Cancer

Direct Binding of DNA by Tumor Suppressor Menin.

Sirt3 inhibits hepatocellular carcinoma cell growth through reducing Mdm2-mediated p53 degradation.